Select outcomes of ASCT for relapsed or refractory FL
| Series . | Reference . | Arm . | No. of patients . | HDCT regimen . | PFS/EFS (%) . | PFS timepoint (y) . | HR . | P . | OS (%) . | OS timepoint (y) . | P . | Comment . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CUP Trial | 16 | Chemotherapy | 24 | 26 | 2 | .003 | 46 | 4 | .07 | RCT, no rituximab | ||
| Unpurged | 33 | CY-TBI | 58 | 71 | ||||||||
| Purged | 32 | 55 | 77 | |||||||||
| EBMT | 49 | Unpurged, no MR | 70 | 35.8 | 10 | ND | 10 | RCT, no rituximab | ||||
| Purged, no MR | 72 | BEAM | 38.7 | ND | ||||||||
| Unpurged, MR | 69 | 48.8 | 0.98 | ND | ||||||||
| Purged, MR | 69 | 52.1 | ND | |||||||||
| EBMT | 67 | CR/PR1 | 131 | BEAC BEAM or TBI-based | 39 | 15 | 60 | 15 | Registry, no rituximab | |||
| No CR/PR1 | 562 | 26 | 44 | |||||||||
| Barts/DFCI | 52 | CR/PR2+ | 121 | CY-TBI | 55 | 5 | 71 | 5 | No rituximab | |||
| Nebraska | 36 | ASCT | 248 | BEAC BEAM R-BEAM, CY-TBI | 44 | 5 | 63 | 5 | No rituximab | |||
| GELA/ GOELAMS | 62 | Chemotherapy | 133 | 39 | 3 | .005 | 63 | 3 | < .001 | Multicenter, prior rituximab in 40% | ||
| ASCT | 42 | BEAM or CY-TBI | 73 | 92 | ||||||||
| NCCN | 44 | CR/PR2+ | 135 | BEAM, CBV or TBI-based | 57 | 3 | 87 | 3 | Multicenter, prior rituximab in 100% | |||
| EBMT | 53 | CR/PR2+ | 726 | BEAM, CY-TBI, other | 48 | 5 | 72 | 5 | Registry, prior rituximab in 53% | |||
| CIBMTR | 39 | CR/PR2+ | 250 | BEAM CBV, CY-TBI, Other | 41 | 5 | 74 | 5 | Registry, FL1 and FL2, prior rituximab in 100% | |||
| CIBMTR | 40 | CR/PR2+ | 136 | BEAM, CBV, CY-TBI, other | 36 | 5 | 59 | 5 | Registry, FL3, prior rituximab in 100% |
| Series . | Reference . | Arm . | No. of patients . | HDCT regimen . | PFS/EFS (%) . | PFS timepoint (y) . | HR . | P . | OS (%) . | OS timepoint (y) . | P . | Comment . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CUP Trial | 16 | Chemotherapy | 24 | 26 | 2 | .003 | 46 | 4 | .07 | RCT, no rituximab | ||
| Unpurged | 33 | CY-TBI | 58 | 71 | ||||||||
| Purged | 32 | 55 | 77 | |||||||||
| EBMT | 49 | Unpurged, no MR | 70 | 35.8 | 10 | ND | 10 | RCT, no rituximab | ||||
| Purged, no MR | 72 | BEAM | 38.7 | ND | ||||||||
| Unpurged, MR | 69 | 48.8 | 0.98 | ND | ||||||||
| Purged, MR | 69 | 52.1 | ND | |||||||||
| EBMT | 67 | CR/PR1 | 131 | BEAC BEAM or TBI-based | 39 | 15 | 60 | 15 | Registry, no rituximab | |||
| No CR/PR1 | 562 | 26 | 44 | |||||||||
| Barts/DFCI | 52 | CR/PR2+ | 121 | CY-TBI | 55 | 5 | 71 | 5 | No rituximab | |||
| Nebraska | 36 | ASCT | 248 | BEAC BEAM R-BEAM, CY-TBI | 44 | 5 | 63 | 5 | No rituximab | |||
| GELA/ GOELAMS | 62 | Chemotherapy | 133 | 39 | 3 | .005 | 63 | 3 | < .001 | Multicenter, prior rituximab in 40% | ||
| ASCT | 42 | BEAM or CY-TBI | 73 | 92 | ||||||||
| NCCN | 44 | CR/PR2+ | 135 | BEAM, CBV or TBI-based | 57 | 3 | 87 | 3 | Multicenter, prior rituximab in 100% | |||
| EBMT | 53 | CR/PR2+ | 726 | BEAM, CY-TBI, other | 48 | 5 | 72 | 5 | Registry, prior rituximab in 53% | |||
| CIBMTR | 39 | CR/PR2+ | 250 | BEAM CBV, CY-TBI, Other | 41 | 5 | 74 | 5 | Registry, FL1 and FL2, prior rituximab in 100% | |||
| CIBMTR | 40 | CR/PR2+ | 136 | BEAM, CBV, CY-TBI, other | 36 | 5 | 59 | 5 | Registry, FL3, prior rituximab in 100% |
BEAM, carmustine, etoposide, cytarabine, and melphalan; CBV, cyclophosphamide, carmustine, and etoposide; CR, complete response; CY, cyclophosphamide; EFS, event-free survival; HDCT, high-dose chemotherapy; MR, maintenance rituximab; ND, no differences; PR1, first partial response; PR2, second partial response; PR2+, beyond second partial response; R-BEAM, rituximab plus BEAM.